iPS cell derived cardiomyocytes
iPS cell derived cardiomyocytes are required in fields such as regenerative medicine and drug discovery.
Heart disease is the leading cause of death in the world. Donor shortage and immune rejection are problems in heart transplantation and surgical operation, and transplantation therapy using iPS cell derived cardiomyocytes is expected.
In addition, many merits are expected by incorporating the test using this iPS cell-derived cardiomyocyte into drug discovery. In addition, there is also the demand for its use in drug discovery and for basic research.
Only small molecules and amino acids (protein/peptide-free)
The demand for iPS cell-derived cardiomyocytes is growing every year in all fields. However, various problems such as maturity and drug responsiveness are preventing the practical use of iPS cell-derived cardiomyocytes. The protein-free method developed at the Kyoto University is a technology that can solve these problems.
High maturity · High purity
We have been able to produce mature cardiomyocytes and highly pure cardiomyocytes with stable properties by using mass culture technique.
The animation is about 1 cm iPS cell-derived cardiomyocyte sheet.
Good drug response
Our cardiomyocytes show drug responsiveness peculiar to mature cardiac muscles.
Highly engrafted cardiomyocytes
As a result of transplantation experiments in rats, Myoridge cardiomyocytes have been found to be highly engrafted cardiomyocytes.